Apotheek De Smet F.
InactiveNo longer registered with the KBO since 03-08-2026; last annual accounts for fiscal year 2025.
Signals
Three signals. The signal on the left, the evidence on the right.
○neutral
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-07-2026, 28 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
28 d early
2024
20 d early
2023
19 d early
2022
24 d early
2021
38 d early
2020
36 d early
2019
57 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
17-09-2026 today31-12-2026 close31-07-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€166k▼ 2.5%
2024 · €170k
2018: €103k
2019: €115k
2020: €140k
2021: €165k
2022: €181k
2023: €174k
2024: €170k
2018 → 2025
Total assets
€167k▼ 2.6%
2024 · €172k
2018: €135k
2019: €145k
2020: €176k
2021: €190k
2022: €185k
2023: €182k
2024: €172k
2018 → 2025
Net result
€-4k▼ 3.9%
2024 · €-4k
2018: €18k
2019: €12k
2020: €25k
2021: €25k
2022: €9k
2023: €-6k
2024: €-4k
2018 → 2025
Working capital
€4k▼ 32.3%
2024 · €6k
2018: €99k
2019: €113k
2020: €139k
2021: €164k
2022: €42k
2023: €425
2024: €6k
2018 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€165k-€181k▲ 9.3%€174k▼ 3.6%€170k▼ 2.4%€166k▼ 2.5%
Operating result€33k-€9k▼ 73.3%€-8k€-6k▲ 27.9%€-6k▼ 1.5%
Net result€25k-€9k▼ 63.1%€-6k€-4k▲ 35.5%€-4k▼ 3.9%
Turnover and EBIT margin not published: the abbreviated or micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €6k in 2025 against €6k in 2024; the loss grows.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €167k
Fixed assets
€161k▼ 1.4%
Current assets
€6k▼ 27.3%
Equity and liabilities €167k
Equity
€166k▼ 2.5%
Debt
€2k▼ 11.5%
The debt ratio falls from 1.2% to 1.1%. Equity and debt are lower.
Key figures and ratios
Solvency
98.9%▲
2024 · 98.8%
Current ratio
3.40▼
2024 · 4.14
Quick ratio
3.40▼
2024 · 4.14
Debt / equity
0.01▼
2024 · 0.01
ROE
-2.6%▼
2024 · -2.4%
ROA
-2.6%▼
2024 · -2.4%
Debt
€2k▼
2024 · €2k
Debt ≤ 1 year
€2k▼
2024 · €2k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€172k€167k▼
Fixed assets21/28€164k€161k▼
Financial fixed assets28€164k€161k▼
Current assets29/58€8k€6k▼
Amounts receivable within one year40/41€5k€6k▲
Other amounts receivable41€5k€6k▲
Cash at bank and in hand54/58€3k€230▼
Equity and liabilities
Total equity and liabilities10/49€172k€167k▼
Equity10/15€170k€166k▼
Contributions10/11€19k€19k=
Reserves13€162k€162k=
Non-distributable reserves130/1€2k-
Reserves not available under the articles1311€2k-
Distributable reserves133€160k€162k▲
Profit (loss) carried forward14€-11k€-15k▼
Amounts payable17/49€2k€2k▼
Amounts payable within one year42/48€2k€2k▼
Trade debts44€2k€2k▼
Suppliers440/4€2k€2k▼
Income statement
Code20242025
Other operating charges640/8€528€544▲
Gross operating margin9900€-5k€-5k▼
Operating profit (loss)9901€-6k€-6k▼
Financial income75/76B€2k€2k▼
Recurring financial income75€2k€2k▼
Financial charges65/66B€114€115▲
Recurring financial charges65€114€115▲
Profit (loss) for the period before taxes9903€-4k€-4k▼
Profit (loss) for the period9904€-4k€-4k▼
Profit (loss) for the period to be appropriated9905€-4k€-4k▼
Appropriation of the result
Profit (loss) to be appropriated9906€-11k€-15k▼
Profit (loss) brought forward from the previous period14P€-6k€-11k▼
The notes to these accounts (5 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
11-08
State Gazette act
Restructuring · End & cessationGeneral meeting · Merger · Accounting effect5 facts ▸
State Gazette act
Restructuring · End & cessation
General meeting · Merger · Accounting effect5 facts ▸
- General meeting, 06/05/2026
- Merger, absorption
- Accounting effect, 01/01/2026
- Dissolution, 2026-05-06
- Power of attorney, Randolph Corbeij
03-07
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema
27-03
State Gazette act
RestructuringMerger · Accounting effect · Permanent representative5 facts ▸
State Gazette act
Restructuring
Merger · Accounting effect · Permanent representative5 facts ▸
- Merger, 3 maart 2026
- Merger, 3 maart 2026
- Merger, 3 maart 2026
- Accounting effect, 1 januari 2026
- Permanent representative, Eveline De Laender
2025
11-07
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema
2024
31-12
Financial
Liquidity quadruplescurrent ratio 4.14
Current ratio from 1.10 to 4.14; short-term debt falls from €4k to €2k.
12-07
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema
2023
31-12
Financial
Weakest financial yearnet €-6k ▼170%
Net result drops to €-6k, the lowest in the series.
07-07
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
23-06
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema
2021
31-12
Financial
Equity above €150kEq €165k ▲17.8%
4 profitable years in a row build equity to €165k.
25-06
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
31-12
Financial
Highest result since 2018net €25k ▲117%
Operating result €37k, net result €25k, both a record.
04-06
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
19-06
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
2018
13-07
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema
2017
12-07
NBB filing
Annual accounts filed
fiscal year 2016 · micro schema
Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
no sitting director, no change since 2024
We have established no sitting directors for this company. We derive directors from published Gazette acts; while there are none, or none read, nothing appears here. That does not mean the company has none: the CBE keeps its own list of function holders, which we do not read.
09-02-2024
Marc Standaert: Resigned as Permanent representative
23-01-2024
Marc Standaert: Resigned as Director
09-11-2023
COOP-APOTHEKEN: Resigned as Director
01-07-2022
De Smet Francine: Resigned as Director
Location & real-estate footprint
Registered office, Gent
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Nieuwevaart 1519000 GentGround area
5,935 m²
Building footprint
663 m²
Volume, LiDAR
2,255 m³
Parcel 44807G0029/00Z002, Flanders · tallest building 4.5 m, ±1 floor. Linked by address, not a title deed.
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44807G0029/00Z002 | Flanders | 5,935 m² | 1 · 663 m² | 4.5 m · 1 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Structure & network
Connections & network
2 connected companiesNetwork connections
Shared address
→
Shared address
→
Acquisitions and mergers
2 transactionsTaken over by:COOP-APOTHEKEN
Taken over by:COOP-АРОТНЕКEN
Similar companies · same sector, comparable size
Rougeardent SRL
BE 1003.844.684
Liège · Eq €166k
CIEL PHARMA
BE 0690.987.220
Brussel · Eq €166k
PHARMACIE REMILI-BASTIN
BE 0872.727.608
Chapelle-lez-Herlaimont · Eq €166k
PHARMACIE PIRENNE
BE 0446.215.143
Soumagne · Eq €165k
VABO PHARMA
BE 0420.027.816
Menen · Eq €166k
Of 5,224 companies in sector 47730 we hold annual accounts for 3,864. 3,581 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded05-11-2007
Fiscal year end31-12
Activities, NACEBEL
47730Retail sale of pharmaceutical products
52310
Sources
Crossroads Bank for EnterprisesNational Bank · 18 filingsAddress and cadastre registers
Data from official sources, last processed on 16-09-2026. Scores and ratios are computed by Checked and are not a credit decision.